Mablink Bioscience
French tech company | Builders Republic
About
Biotech company developing next-generation antibody-drug conjugates (ADCs) against cancer — built on its proprietary PSARLink hydrophilic linker platform, used for its own pipeline and licensed to partners.
Key facts
- Status
- Rachetée
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2018
- City
- LYON
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 2
- Amount raised
- 35 M€
Operations
- Series A · 2022
- Seed · 2021
Investors
- Angelor
- Crédit Agricole Création
- Elaia Partners
- Fondation Fournier-Majoie
- Merieux Partners
- Relyens Innovation Santé
- Sofinnova
- UI Investissement
Notes
Rachetée par Eli Lilly (accord annoncé le 18/10/2023, finalisé le 01/12/2023).